UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038798
Receipt number R000044232
Scientific Title Effect of hyper protect capsule on viability of probiotics that reach to the large intestines
Date of disclosure of the study information 2019/12/06
Last modified on 2024/01/10 23:08:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of hyper protect capsule on viability of probiotics that reach to the large intestines

Acronym

Viability of probiotics that encapsulated in hyper protect capsule to the large intestines

Scientific Title

Effect of hyper protect capsule on viability of probiotics that reach to the large intestines

Scientific Title:Acronym

Viability of probiotics that encapsulated in hyper protect capsule to the large intestines

Region

Japan


Condition

Condition

N/A(healthy adults)

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verify the functionality of the hyper protect capsule.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Evaluation of ingested viable probiotic bacteria that reached to colon.
: The fecal number of viable bacteria ingested (Bifidobacterium)

Key secondary outcomes

Analysis on gut microbiota by 16S metagenomic analysis
: Evaluation of the abundance of Bifidobacterium spp. in the feces


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Test food A;Take a hyper protect capsules which contain Bifidobacterium in a package. (Single ingestion)

Interventions/Control_2

Test food B;Take a Bifidobacterium in a package. (Single ingestion)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Healthy men and women of 20 years or older at the time of consent acquisition
(2) The number of Bifidobacterium spp.
(3) Person who the number of defecation per day is less than three times on average
(4) Persons with stool characteristics (Bristol scale) 3 or 4
(5) BMI has a standard range (18.5-25)
(6)A person who receives the explanation of the clinical trial in advance, understands the contents, agrees to the purpose, and obtains written consent from the person

Key exclusion criteria

(1) Those who underwent open surgery within half a year of the trial start
(2) Those who have taken antibiotics for more than one week within half a year of the study start
(3) Persons who are allergic to the test food
(4) Those who plan to change their lifestyle significantly during the examination period
(5) Persons who are chronically prone to diarrhea (meaning stools with mud or watery stools)
(6) Patients with a history of significant liver dysfunction, renal dysfunction, or cardiovascular disease that is considered inappropriate for this study
(7) A person suspected of having a chronic or acute infection
(8) Those who are pregnant or nursing or who may be pregnant
(9) Those who participated in other clinical trials within the past 1 month
(10) Others who were judged by the study investigator to be inappropriate for this study

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Hirosato
Middle name
Last name Kawakami

Organization

Morishita Jintan Co., Ltd.

Division name

Health Care Product Department

Zip code

540-8566

Address

2-40,Tamatsukuri 1-chome, Chuo-ku, Osaka

TEL

06-6761-1131

Email

h-kawakami@jintan.co.jp


Public contact

Name of contact person

1st name Mamiko
Middle name
Last name Kohno

Organization

Morishita Jintan Co., Ltd.

Division name

Health Care Product Department

Zip code

101-0043

Address

10, Kanda Tomiyamacho, Chiyoda-ku, Tokyo Ascend Kanda Building 6F

TEL

03-6206-8138

Homepage URL


Email

m_kohno@jintan.co.jp


Sponsor or person

Institute

Morishita Jintan Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Morishita Jintan Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Animal Function Science Laboratory, Department of Applied Biological Sciences, Faculty of Agriculture,Setsunan University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Social medical corporation sokuinkai kouyou Clinic Clinical Trial Review Committee

Address

3-9, Kouyou-cho, Kitahiroshima-shi, Hokkaido

Tel

011-372-3900

Email

k-ohno@cli-creative.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 23 Day

Date of IRB

2020 Year 07 Month 31 Day

Anticipated trial start date

2019 Year 12 Month 06 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 12 Month 05 Day

Last modified on

2024 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044232


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name